Ameriprise Financial Inc. Sells 9,662 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Ameriprise Financial Inc. lessened its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 106,956 shares of the company's stock after selling 9,662 shares during the quarter. Ameriprise Financial Inc. owned 0.23% of Omnicell worth $4,762,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its stake in shares of Omnicell by 51.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. bought a new position in Omnicell in the fourth quarter worth approximately $37,000. Van ECK Associates Corp boosted its stake in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock worth $44,000 after acquiring an additional 315 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Omnicell during the 4th quarter valued at $53,000. Finally, First Horizon Advisors Inc. grew its position in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after acquiring an additional 355 shares during the period. Institutional investors own 97.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on OMCL shares. Bank of America raised their target price on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday. Piper Sandler reaffirmed an "overweight" rating on shares of Omnicell in a research note on Friday. JPMorgan Chase & Co. cut their price objective on Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Wall Street Zen raised shares of Omnicell from a "hold" rating to a "buy" rating in a report on Tuesday, May 20th. Finally, Benchmark lowered their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Omnicell presently has an average rating of "Moderate Buy" and an average price target of $44.83.

Omnicell Price Performance

OMCL traded up $1.38 on Tuesday, hitting $29.61. 689,821 shares of the company's stock traded hands, compared to its average volume of 565,477. The company's 50 day simple moving average is $30.81 and its 200-day simple moving average is $38.47. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.75. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 109.67, a P/E/G ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The firm had revenue of $269.67 million for the quarter, compared to analysts' expectations of $260.18 million. During the same quarter last year, the business posted $0.03 earnings per share. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. As a group, research analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.